Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Superselective adrenal artery embolization vs spironolactone in idiopathic hyperaldosteronism
ChiCTR2300079135Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone in primary aldosteronism (PA) (2 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Blood pressure, Serum potassium and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
spironolactone
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on ChiCTR2300079135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079135.